Gilead Sciences (GILD) News Today $92.59 -0.37 (-0.40%) As of 01:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Nisa Investment Advisors LLC Cuts Position in Gilead Sciences, Inc. (NASDAQ:GILD)Nisa Investment Advisors LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 408,793 shares of the biopharmaceutical company's stock after selling 30,223 shares duJanuary 22 at 7:41 AM | marketbeat.comGenesis Private Wealth LLC Purchases New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Genesis Private Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 3,915 shares of the biopharmaceutical company's stock, valued at approximately $362,000. SeveralJanuary 22 at 7:33 AM | marketbeat.comCantor Fitzgerald Comments on Gilead Sciences FY2025 EarningsGilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Gilead Sciences in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will postJanuary 22 at 7:19 AM | marketbeat.comFort Washington Investment Advisors Inc. OH Acquires 53,617 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Fort Washington Investment Advisors Inc. OH raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 376,047 shares of the biopharmaceutical company's sJanuary 22 at 5:56 AM | marketbeat.comIs Gilead Sciences (GILD) Among Billionaire Steve Cohen’s Top Stock Picks?January 21 at 7:22 PM | insidermonkey.comIs Gilead Sciences (GILD) Among Billionaire Steve Cohen’s Top Stock Picks?January 21 at 6:12 PM | msn.comBrookmont Capital Management Raises Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Brookmont Capital Management lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 51,083 shares of the biopharmaceutical company's stock after purchasing an additional 7,322 shaJanuary 21 at 7:09 AM | marketbeat.comCrossmark Global Holdings Inc. Buys 8,741 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Crossmark Global Holdings Inc. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 540,220 shares of the biopharJanuary 21 at 7:00 AM | marketbeat.comMerit Financial Group LLC Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Merit Financial Group LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 40.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,707 shares of the biopharmaceutical companyJanuary 21 at 3:34 AM | marketbeat.comM.E. Allison & CO. Inc. Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)M.E. Allison & CO. Inc. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 3,633 shares of the biopharmaceutical company's stock, vJanuary 20 at 7:15 AM | marketbeat.comHB Wealth Management LLC Purchases 8,406 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)HB Wealth Management LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 46.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,411 shares of the biopharmaceutical company's stock after purchasing an additJanuary 20 at 4:24 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Hennion & Walsh Asset Management Inc.Hennion & Walsh Asset Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,237 shares of the biopharmaceutical comJanuary 20 at 3:24 AM | marketbeat.comQ2 EPS Estimates for Gilead Sciences Lifted by AnalystJanuary 20 at 2:10 AM | americanbankingnews.comZacks Research Boosts Earnings Estimates for Gilead SciencesGilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities researchers at Zacks Research upped their Q2 2025 EPS estimates for shares of Gilead Sciences in a research note issued on Thursday, January 16th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will posJanuary 20 at 1:37 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Sees Significant Growth in Short InterestGilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 25,660,000 shares, an increase of 16.7% from the December 15th total of 21,980,000 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average daily volume of 6,460,000 shares, the short-interest ratio is currently 4.0 days.January 20 at 12:32 AM | marketbeat.comLiberty One Investment Management LLC Sells 7,350 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Liberty One Investment Management LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 93,962 shares of the biopharmaceutical company's stockJanuary 19 at 7:51 AM | marketbeat.comNexus Investment Management ULC Trims Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Nexus Investment Management ULC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 239,813 shares of the biopharmaceutical company'sJanuary 19 at 6:25 AM | marketbeat.comPremier Path Wealth Partners LLC Has $744,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)Premier Path Wealth Partners LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 89.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,052 shares of the biopharmaceutical company'January 19 at 5:18 AM | marketbeat.comArkadios Wealth Advisors Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)Arkadios Wealth Advisors cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 30.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,510 shares of the biopharmaceutical company's sJanuary 19 at 5:06 AM | marketbeat.comWestend Capital Management LLC Acquires 57,632 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Westend Capital Management LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 71.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 138,642 shares of the biopharmaceutical company's stock after purJanuary 18, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Cohen Klingenstein LLCCohen Klingenstein LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 42.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,700 shares of the biopharmaceutical company's stock afJanuary 18, 2025 | marketbeat.comEarnings Preview: What to Expect From Gilead Sciences’ ReportJanuary 18, 2025 | msn.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Verity & Verity LLCVerity & Verity LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 378,102 shares of the biophaJanuary 18, 2025 | marketbeat.comWedge Capital Management L L P NC Sells 86,409 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Wedge Capital Management L L P NC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 21.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 313,225 shares of the biopharmaceutical company's stock aJanuary 18, 2025 | marketbeat.comPark Avenue Securities LLC Buys 6,878 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Park Avenue Securities LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,753 shares of the biopharmaceutical compJanuary 18, 2025 | marketbeat.comBoston Common Asset Management LLC Sells 53,301 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Boston Common Asset Management LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 115,982 shares of the biopharmaceutical company's stoJanuary 17, 2025 | marketbeat.comAvanza Fonder AB Purchases New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)Avanza Fonder AB bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 127,115 shares of the biopharmaceutical company's stock, valued at approximately $11,742,000. A numberJanuary 17, 2025 | marketbeat.comOccidental Asset Management LLC Acquires 3,980 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Occidental Asset Management LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,616 shares ofJanuary 17, 2025 | marketbeat.comAndrew D. Dickinson Sells 2,500 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) StockJanuary 17, 2025 | insidertrades.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Ritholtz Wealth ManagementRitholtz Wealth Management boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 80.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,228 shares of the biopharmaceutJanuary 17, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Stock Position Trimmed by Sicart Associates LLCSicart Associates LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 105,930 shares of the biopharmaceutical company's stJanuary 17, 2025 | marketbeat.comGateway Investment Advisers LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Gateway Investment Advisers LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,654 shares of the biopharmaceutical company's stockJanuary 17, 2025 | marketbeat.comGilead Sciences CFO sells shares worth $228,375January 16, 2025 | msn.comInsider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD)January 16, 2025 | gurufocus.comGilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $228,375.00 in StockGilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.January 16, 2025 | marketbeat.comIs Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy?January 16, 2025 | insidermonkey.comGilead Sciences: Strategic Growth and Optimism Amidst Market ChallengesJanuary 16, 2025 | markets.businessinsider.comGilead reportedly settles CDC patent dispute over HIV drugsJanuary 16, 2025 | msn.comIs Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy?January 16, 2025 | msn.comRovin Capital UT ADV Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Rovin Capital UT ADV decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 28.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,951 shares of the biopharmaceutical company's stocJanuary 16, 2025 | marketbeat.comUSA Financial Formulas Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)USA Financial Formulas acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 16,664 shares of the biopharmaceutical company's stock, valued at approximatelJanuary 16, 2025 | marketbeat.comAssenagon Asset Management S.A. Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Assenagon Asset Management S.A. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 75.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 585,076 shares of the biopharmaceuticalJanuary 16, 2025 | marketbeat.comGilead Sciences, US government settle patent case over HIV prevention drugsJanuary 15, 2025 | reuters.comGlobal Financial Private Client LLC Boosts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Global Financial Private Client LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1,222.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,068 shares of the biopharmaceutical company'January 14, 2025 | marketbeat.comWright Investors Service Inc. Cuts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Wright Investors Service Inc. reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 24.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 48,181 shares of the biopharmaceutical company's stock after selling 1January 14, 2025 | marketbeat.comGilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)January 13, 2025 | seekingalpha.comGilead Sciences: Supreme Court Case and New Innovations Drive Buy RatingJanuary 13, 2025 | markets.businessinsider.comGilead’s new HIV prevention drug lenacapavir will ‘change the face of HIV,’ says CEO Daniel O’DayJanuary 13, 2025 | msn.comCapital Investment Advisors LLC Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)Capital Investment Advisors LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 387,492 shares of the biopharmaceutical company's stock after purchasJanuary 13, 2025 | marketbeat.comTT International Asset Management LTD Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)TT International Asset Management LTD lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 68.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,675 shares of the biopharmaceutical comJanuary 13, 2025 | marketbeat.com Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address GILD Media Mentions By Week GILD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼1.200.63▲Average Medical News Sentiment GILD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼4421▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMGN News Today VRTX News Today REGN News Today ALNY News Today BIIB News Today UTHR News Today NBIX News Today INCY News Today BMRN News Today EXEL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GILD Stock Alerts